Journals / Turkish Journal of Hematology / 2017 / Cilt: 34 - Sayı: 2

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model

Kronik Miyeloid Lösemi Tedavi Dozunda Nilotinib'in Gonadotoksik Etkilerinin Fare Modelinde Gösterilmesi

Pages
137–142
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We have demonstrated that even though spermatogenesis is preserved, folliculogenesis is inhibited by the usage of a continuous nilotinib treatment dose in chronic myeloid leukemia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility.
📊
Key Findings & Data:Materials and Methods: Ten male and ten female mice were orally treated with nilotinib at 20 mg/kg body weight dissolved in drinking water daily for 2 months.
💡
Conclusion & Impact:Conclusion: We have demonstrated that even though spermatogenesis is preserved, folliculogenesis is inhibited by the usage of a continuous nilotinib treatment dose in chronic myeloid leukemia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility. The aim of this study is to determine the effect of nilotinib, which is used routinely to treat chronic myeloid leukemia, on spermatogenesis and folliculogenesis by using histopathological parameters. Materials and Methods: Ten male and ten female mice were orally treated with nilotinib at 20 mg/kg body weight dissolved in drinking water daily for 2 months. Results: When compared with the control group, a statistically significant decrease was demonstrated in the total follicle numbers of the female mice in the nilotinib group (268±110 vs. 170±60; p=0.03). Active spermatogenesis was observed in each tubule sample taken from the mice in the control and nilotinib groups. Spermatogenic activity was similar in the two groups. Conclusion: We have demonstrated that even though spermatogenesis is preserved, folliculogenesis is inhibited by the usage of a continuous nilotinib treatment dose in chronic myeloid leukemia.

Özet

Amaç: Tirozin kinaz inhibitörlerinin; potansiyel gonadotoksisite ve döllenme üzerindeki olası etkileri hakkında kesin veriler bulunmamaktadır. Bu çalışmanın amacı sağlıklı fare modelinde nilotinib tedavisinin fertilite üzerine etkilerini araştırmaktır. Gereç ve Yöntemler: On erkek ve on dişi fareye 20 mg/kg/gün nilotinib içme suyuna katılarak 2 ay süre ile verildi. Bulgular: Folikül sayılarında nilotinib verilen dişi fare grubunda kontrol grubuna göre istatistiksel olarak anlamlı bir azalma olduğu gözlendi (268±110 vs. 170±60; p=0,03). Kontrol ve nilotinib gruplarındaki farelerden alınan her seminifer tübül örneğinde spermatid veya spermatozoa olan aktif spermatogenez gözlendi. Spermatojenik aktivite indeksi her iki grupta da benzerdi. Sonuç: Bizim çalışmamız ile kronik miyeloid lösemide tedavi dozunda ve uzun süreli nilotinib kullanımı ile spermatogenez korunurken folikülogenezin baskılandığı gösterilmiştir.

🔖

Cite This Article

CENGİZ, G. S., ÖZKAVUKÇU, S., SEVAL, M. M., AYLI, M. (2017). Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model. Turkish Journal of Hematology, Cilt: 34 - Sayı: 2, 137–142. https://ajindex.com/articles/413081

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-141.
  2. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-1942. Chuah C. Imatinib does not impair gonadal function. Leuk Res 2012;36:262- 263. Nilsson EE, Detzel C, Skinner MK. Platelet-derived growth factor modulates the primordial to primary follicle transition. Reproduction 2006;131:1007- 1015. Mauduit C, Hamamah S, Benahmed M. Stem cell factor/c-kit system in spermatogenesis. Hum Reprod Update 1999;5:535-545.
  3. Mariani S, Basciani S, Arizzi M, Spera G, Gnessi L. PDGF and the testis. Trends Endocrinol Metab 2002;13:11-17.
  4. Nurmio M, Toppari J, Zaman F, Andersson AM, Paranko J, Söder O, Jahnukainen K. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl 2007;30:366-376.
  5. Shash E, Bassi S, Cocorocchio E, Colpi GM, Cinieri S, Peccatori FA. Fatherhood during imatinib. Acta Oncol 2011;50:734-735.
  6. Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L, Cambiaghi N, Pogliani E, Corneo G, Ginessi L. Gynocomastia in men with chronic myeloid leukemia after imatinib. Lancet 2003;361:1954- 1956.
  7. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988:61:1441-1446.
  8. Gosden RG, Laing SC, Felicio LS, Nelson JF, Finch CE. Imminent oocyte exhaustion and reduced follicular recruitment mark the transition to acyclicity in aging C57BL/6J mice. Biol Reprod 1983;28:255-260.
  9. Schultheis B, Nijmeijer BA, Yin H, Gosden RG, Melo JV. Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res 2012;36:271-274.
  10. Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med 2008;358;1079-1080. Apperley J. CML in pregnancy and childhood. Best Pract Res Clin Haematol 2009;22:455-474.
  11. Zhou L, You JH, Wu W, Li JM, Shen ZX, Wang AH. Pregnancies in patients with chronic myeloid leukemia treated wit